TherOx Completes Financing as It Prepares for AMI Therapy System Launch

5/7/18: Supports U.S. market introduction of SuperSaturated Oxygen Therapy for improved AMI patient 0utcomes

TherOx AMI Study for Improved Patient Outcomes Meets Primary Endpoint

The purpose of this study was to confirm the safety and effectiveness of Supersaturated Oxygen (SSO2) Therapy in the treatment of anterior AMI patients who have undergone successful percutaneous coronary intervention with stenting within six hours of experiencing AMI symptoms.

TherOx Completes Enrollment in Study of Next-Generation Therapy System Designed to Improve AMI Outcomes

TherOx, Inc., is a privately held medical device company focused on improved treatment of Acute Myocardial Infarction.